Abstract
Subcutaneous daratumumab (DARZALEX (R)) co-formulated with recombinant human hyaluronidase (DARZALEX FASPRO (R)) is approved in several countries, inc......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
